EUVIMEDEUVIMED entdecken
Crossref

Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia

Jae Duck Choi, Tag Keun Yoo, Jung Yoon Kang, Hyuk-Dal Jung, Jun Ho Lee

International Urology and Nephrology · 2023

DOI: 10.1007/s11255-023-03476-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, 2023. Verfasst von Jae Duck Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Kor…. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To assess adherence to combination therapy comprising α-adrenergic blocker (AB) and 5α-reductase inhibitor (5ARI) for benign prostatic hyperplasia (BPH) in a real-world setting and whether lower urinary tract symptoms (LUTS) will relapse after discontinuing one medication from long-term combination therapy. METHODS: BPH/LUTS patients receiving initial AB +5ARI combination therapy for at least 1 year between January 2012 and January 2017 were retrospectively analyzed. The patients were classified into DC-AB group (n = 65, AB discontinued) and DC-5ARI group (n = 77, 5ARI discontinued) and followed up. Clinical effects were assessed at baseline and annually using the International Prostatic Symptoms Score (IPSS), quality of life (QoL) index, total prostate volume (TPV), maximal flow rate (Qmax), and prostate-specific antigen (PSA) level. RESULTS: Of total 1783 patients, 809 (45.4%) patients were identified with more than 1-year combination therapy. After withdrawal of one medication from combination therapy, the TPV progression (27.6% vs. - 10.8%; P < 0.001) and the requirement for prostate surgery (14.3% vs. 6.1%; P = 0.038) were significantly higher in the DC-5ARI group than in the DC-AB group. The rate of resuming combination therapy was significantly higher in the DC-5ARI group than in the DC-AB group (38.9% vs. 23.0%; P = 0.009). CONCLUSIONS: Adherence to combination BPH therapy is relatively low. Although patients adhered to combination therapy for more than 1 year, a higher risk of requiring prostate surgery or resuming combination therapy was observed in patients who discontinued 5ARI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaLower Urinary Tract SymptomsMaleHumansQuality of LifeRetrospective StudiesDrug Therapy, Combination5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsOxidoreductases

Stichwörter der Autor:innen

Adrenergic antagonistBenign prostate hyperplasiaLower urinary tract symptomProstateQuality of life

Substanzen

5-alpha Reductase InhibitorsAdrenergic alpha-AntagonistsOxidoreductases

Autor:innen und Institutionen

  • Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Korea.
  • Department of Urology, Nowon Eulji Medical Center, Eulji University School of Medicine, 68, Hangeulbiseok-ro, Nowon-gu, Seoul, 01830, Republic of Korea. bonanza96@eulji.ac.kr.

Zitieren

APA

Choi, J. D., Yoo, T. K., Kang, J. Y., Jung, H. D., & Lee, J. H. (2023). Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia. International Urology and Nephrology. https://doi.org/10.1007/s11255-023-03476-6

Vancouver

Choi JD, Yoo TK, Kang JY, Jung HD, Lee JH. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia. International Urology and Nephrology. 2023. doi:10.1007/s11255-023-03476-6

BibTeX
@article{Choi2023,
  author = {Choi, Jae Duck and Yoo, Tag Keun and Kang, Jung Yoon and Jung, Hyuk-Dal and Lee, Jun Ho},
  title = {Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia},
  journal = {International Urology and Nephrology},
  year = {2023},
  doi = {10.1007/s11255-023-03476-6}
}
Kostenlos starten →